SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced new data today at ASCO GU 2023 demonstrating that its multimodal artificial intelligence (MMAI) prognostic biomarker can help bring more personalized treatment to men with localized prostate cancer. The biomarker was successfully validated across six phase III randomized trials with long-term follow-up to be independently prognostic over standard cl